Glaucoma Eye Drops Greatly Reduce Risk of Vision Loss
Prostaglandin analogue eye drops including brand names Xalatan, Lumigan, and Travatan Zcan greatly reduce risk of vision loss in people with open angle glaucoma (OAG). This condition is one of the leading causes of blindness. Results of first placebo-controlled trial to assess the drops/ vision-preserving effect was published in December 2014 in The Lancet.
A release from the publishers quotes lead author explains David Garway-Heath, International Glaucoma Association Professor of Ophthalmology at the NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK, as saying, “Medication to lower raised eye pressure has been used for decades as the main treatment for OAG to delay progressive vision loss. But, until now, the extent to which the most frequently prescribed class of pressure-lowering drugs (prostaglandin analogues) have a protective effect on vision was not known. Our findings offer solid proof to patients and practitioners that the visual deterioration caused by glaucoma can be reduced using this treatment.”
The release explains that OAG is the most common form of glaucoma affecting 45 million people worldwide andprojected to increase to 53 million in 2020 and 80 million in 2040. Vision loss from glaucoma occurs when the optic nerve is damaged. In most cases, increased pressure inside the eye (intraocular pressure), is thought to contribute to this damage.
The United Kingdom Glaucoma Treatment Study (UKGTS) recruited 516 newly diagnosed, previously untreated individuals with OAG from 10 hospitals across the UK.
Half were randomly assigned to daily pressure-lowering eye drops (latanoprost 0.005%) and the other half to a matching placebo. Over the course of 2 years, participants underwent frequent visual field tests to identify glaucoma deterioration to an extent that would not be noticed by the patient.
In the 59 patients in the placebo group and 35 patients in the latanoprost group whose vision deteriorated during the study period, the risk of visual deterioration was over 50% lower in the group treated with daily pressure-lowering eye drops compared to those using placebo drops over 2 years. Importantly, a significant difference in treatment effects could be seen between the groups after just 12 months. Eighteen serious adverse events were reported (9 in the placebo group and 9 in the latanoprost group) but none were viewed as related to latanoprost.
According to Professor Garway-Heath, “Normally, observation periods in trials are at least 5 years. We have shown that with more frequent testing, data can be collected using shorter observation periods. This will bring considerable benefits including speeding up novel drug development, reducing costs, and increasing the likelihood of bringing new drugs to patients.”*